VeriMomginsenoside rh4 est-il sûr pendant la grossesse ?
No harmonised CLP classification, no SCCS or CIR cosmetic safety assessment specific to ginsenoside Rh4 was found and there are no published reproductive/teratology studies for Rh4; therefore hazard is default 0. However, some ginsenosides show estrogen-related or bioactive signaling effects in vitro and Rh4 shows biological activity in cultured cells and animal models (e.g. anti‑tumor, AMPK, gut/liver signaling), so a theoretical mechanistic concern (structural/class similarity to other ginsenosides) is noted (m=1). Topical cosmetic exposure is expected to give negligible systemic absorption for a large polar triterpenoid glycoside, so exposure is scored e=0 for pregnant adults. Sources: PubMed studies on Rh4 activity, ECHA substance info (no harmonised CLP), EWG ingredient entry.
Related ingredients
Frequently asked questions
- ginsenoside rh4 est-il sûr pendant la grossesse ?
- No harmonised CLP classification, no SCCS or CIR cosmetic safety assessment specific to ginsenoside Rh4 was found and there are no published reproductive/teratology studies for Rh4; therefore hazard is default 0. However, some ginsenosides show estrogen-related or bioactive signaling effects in vitro and Rh4 shows biological activity in cultured cells and animal models (e.g. anti‑tumor, AMPK, gut/liver signaling), so a theoretical mechanistic concern (structural/class similarity to other ginsenosides) is noted (m=1). Topical cosmetic exposure is expected to give negligible systemic absorption for a large polar triterpenoid glycoside, so exposure is scored e=0 for pregnant adults. Sources: PubMed studies on Rh4 activity, ECHA substance info (no harmonised CLP), EWG ingredient entry.
- ginsenoside rh4 est-il sûr pendant l'allaitement ?
- No data showing Rh4 transfers in breastmilk or causes reproductive/lactation toxicity; no regulatory flags (harmonised CLP / SCCS / CIR). Theoretical mechanistic concern retained (m=1) because ginsenosides as a class have bioactivity in vitro and some other ginsenosides have shown estrogen receptor interactions in studies. Expected topical exposure and transfer to milk is low → e=0 for topical use. Relevant data on whole‑ginseng in LactMed highlights general ginseng concerns but does not provide Rh4‑specific breastfeeding data.
- ginsenoside rh4 est-il sûr pour la peau de bébé ?
- No infant‑specific reproductive or developmental toxicity data for Rh4 and no regulatory reproductive classification were identified, so hazard remains 0. Mechanistic score not increased because there is no infant‑specific mechanistic evidence. Exposure for baby skin is increased by +1 from adult (adult e=0 → baby e=1) because infant skin has higher permeability and surface‑area‑to‑weight; Rh4 is not demonstrated to be non‑absorbable. No data were found showing topical Rh4 causes adverse effects in infants 0–3 y.
- Comment VeriMom évalue-t-il ginsenoside rh4 ?
- VeriMom évalue ginsenoside rh4 à 93/100 (pas de risques connus) sur la base du statut EU CosIng, des classifications ECHA et des études PubMed.
- Quelles sont les alternatives sûres à ginsenoside rh4 pendant la grossesse ?
- Consultez notre liste d'alternatives sûres à ginsenoside rh4 basée sur une fonction similaire et une classification sans risques connus.
Vérifiez chaque étiquette en 2 secondes
Obtenez VeriMom gratuitement — scannez n'importe quel produit et voyez le score de sécurité grossesse instantanément.
Avis Médical
Ces informations sont fournies à titre éducatif uniquement et ne constituent pas un avis médical. Les scores de sécurité sont basés sur des données accessibles au public et peuvent ne pas refléter tous les risques. Consultez toujours votre professionnel de santé avant d'utiliser tout produit pendant la grossesse ou l'allaitement.